7.27
+4.91%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Avalo Therapeutics
From its filings with the US Securities and Exchange Commission
Avalo Therapeutics is based in Wayne, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AVTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $59,000 and a net loss of $78.3m. At that date it held total assets of $116.5m and shareholders' equity of $83.0m.
We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Our current focus is on completing the Phase 2 (“LOTUS”) trial evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our Phase 3 trial(s).
We are advancing a pipeline that emphasizes a high-value and potentially best-in-class and best-in-disease biologics for immune mediated inflammatory diseases.
Our lead product candidate, abdakibart (AVTX-009), is a high affinity, highly potent humanized IgG mAb designed to specifically inhibit IL-1β and block downstream inflammatory pathways. Abdakibart (AVTX-009) is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (“IL-1β”) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases. It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Nov 2015
- Employees
- 33
- Website
- avalotx.com ↗
- Head office
- 1500 LIBERTY RIDGE DRIVE, WAYNE, PA, 19087
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Michael HeffernanIndependent Chairman of the Board
- Dr. Garry NeilPresident, Chief Executive Officer, Director, since 2020$7.2m
- Mr. Christopher SullivanChief Financial Officer$2.9m
- Dr. Mittie DoyleChief Medical Officer$3.0m
- Ms. Jennifer RileyChief Strategy Officer
- Mr. Paul VarkiChief Legal Officer
- Mr. Mitchell ChanIndependent Director$362,475
- Dr. Jonathan GoldmanIndependent Director$341,165
- Dr. Rita JainIndependent Director
- Mr. Aaron KantoffIndependent Director$341,121
- Dr. Gilla KaplanIndependent Director$360,633
- Mr. Kevin LindIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 65
- Social
- 73
- Governance
- 46
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is a clinical stage biotechnology firm focused on immune dysregulation therapies targeting the LIGHT-signaling network.
- Pipeline includes AVTX-002 and AVTX-008, both targeting high-value potential first-in-class biologics.
- Headquartered in Rockville, Maryland with an IPO date of 2015-11-13.
Weaknesses
- Company employs only 33 employees, indicating a small operational scale.
- The source description mentions 20 full-time employees, conflicting with the provided 33 employees.
- The company's focus on a single therapeutic network (LIGHT-signaling) may limit diversification.
Opportunities
- Advancing AVTX-002 for non-eosinophilic asthma, Crohn's Disease, and COVID-19 ARDS presents multiple market applications.
- AVTX-008's evaluation for several immune dysregulation disorders could expand therapeutic reach.
- The biotechnology sector's growth in immune dysregulation treatments offers potential market expansion.
Threats
- The source description's conflicting employee count (20 vs 33) may indicate internal operational issues.
- Dependence on a single therapeutic network (LIGHT-signaling) increases vulnerability to scientific or market shifts.
- Biotechnology companies face high R&D costs and regulatory hurdles for new therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.